Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07251829
PHASE2

Neoadjuvant Embolization and Cytoreduction in Prostate Cancer

Sponsor: Srinivas Raman

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to find out whether prostate artery embolization (PAE) can help prevent or lessen urinary side effects caused by radiotherapy (RT) in people with prostate cancer, especially those who have larger prostates or urinary symptoms before treatment. The main questions this study aims to answer are: * Does PAE before RT reduce the severity of urinary side effects from RT? * Does PAE affect the rates of genitourinary (GU) or gastrointestinal (GI) side effects after RT? Researchers will look at changes in urinary symptoms from the start of the study to 6 months after PAE. They will also record any GU or GI side effects related to RT. Participants will receive prostate artery embolization before starting radiotherapy, and complete questionnaires and assessments about GU and GI functions before and after treatment.

Official title: Neoadjuvant Embolization and Cytoreduction to Ameliorate Radiotherapy Toxicity in Prostate Cancer

Key Details

Gender

MALE

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

35

Start Date

2026-02

Completion Date

2027-12

Last Updated

2025-11-26

Healthy Volunteers

No

Interventions

PROCEDURE

Prostatic Artery Embolization

PAE is a minimally invasive procedure that involves embolizing the arteries supplying the prostate, leading to its shrinkage.